natgillin/translations-raw huggingface dataset:
No dose adjustments are recommended in obese or low body weight patients.
Ne preporučuje se prilagođavanje doze u pretilih bolesnika ili bolesnika niske tjelesne težine.
No dose adjustments are required for elderly patients (see section 5.2).
Nije potrebno prilagođavati dozu za starije bolesnike (vidjeti dio 5.2).
No dose adjustments are required for patients with hepatic impairment (see section 5.2).
Nije potrebno prilagođavati dozu za bolesnike s oštećenjem jetre (vidjeti dio 5.2).
No dose adjustments are required for patients with mild renal impairment and multiple myeloma or mantle cell lymphoma.
Nisu potrebne prilagodbe doza za bolesnike s blagim oštećenjem funkcije bubrega i multiplim mijelomom ili limfomom plaštenih stanica .
No dose adjustments are required for patients with mild renal impairment and multiple myeloma or mantle cell lymphoma.
Nisu potrebne prilagodbe doza za bolesnike s blagim oštećenjem funkcije bubrega i multiplim mijelomom ili limfomom plaštenih stanica.
No dose adjustments are required for patients with mild renal impairment and multiple myeloma, myelodysplastic syndromes, or mantle cell lymphoma.
Nisu potrebne prilagodbe doza za bolesnike s blagim oštećenjem funkcije bubrega i multiplim mijelomom, mijelodisplastičnim sindromima ili limfomom plaštenih stanica.
No dose adjustments are required for patients with renal impairment (see section 5.2).
Nije potrebno prilagođavati dozu za bolesnike s oštećenjem bubrega (vidjeti dio 5.2).
No dose adjustments are required in elderly patients (see section 5.2).
Nije potrebno prilagođavati dozu za starije bolesnike (vidjeti dio 5.2).
No dose adjustments are required in patients with hepatic impairment (see section 5.2).
Nije potrebno prilagođavati dozu za bolesnike s oštećenjem jetre (vidjeti dio 5.2).
No dose adjustments are required in patients with mild or moderate renal impairment (see section 5.2).
Nije potrebno prilagođavati dozu u bolesnika s blagim ili umjerenim oštećenjem bubrežne funkcije (vidjeti dio 5.2).
No dose adjustments are required in patients with renal impairment (see section 5.2).
Nije potrebno prilagođavati dozu za bolesnike s oštećenjem bubrega (vidjeti dio 5.2).
No dose adjustments of Orkambi are necessary based on gender.
Nisu potrebne prilagodbe doze lijeka Orkambi na temelju spola.
No dose adjustments of ZALTRAP is required in the older people.
Nije potrebno prilagođavati dozu lijeka ZALTRAP u starijih osoba.
No dose modification is required.
Nije potrebno prilagođavati dozu.
No dose modification of dabrafenib is required when taken in combination with trametinib for confirmed cases of RVO or RPED.
Nije potrebna prilagodba doze dabrafeniba kada se uzima u kombinaciji s trametinibom u bolesnika s potvrđenom dijagnozom okluzije mrežnične vene (engl. retinal vein occlusion, RVO) i odvajanja pigmentnog epitela mrežnice (engl. retinal pigment epithelial detachment, RPED).
No dose modification of dabrafenib is required when taken in combination with trametinib.
Nije potrebna prilagodba doze dabrafeniba kada se koristi u kombinaciji s trametinibom.
No dose modification of trametinib is required when taken in combination with dabrafenib.
Nije potrebna prilagodba doze trametiniba kada se koristi u kombinaciji s dabrafenibom.
No dose modification of trametinib is required when taken in combination with dabrafenib.
Nije potrebno prilagođavanje doze trametiniba kada se uzima u kombinaciji s dabrafenibom.
No dose modifications are necessary in elderly patients with normal renal function.
U starijih bolesnika s normalnom funkcijom bubrega nije potrebno prilagođavati dozu.
No dose modifications are required for uveitis as long as effective local therapies can control ocular inflammation.
Nije potrebna prilagodba doze kod uveitisa sve dok učinkovita lokalna terapija može kontrolirati upalu oka.
No dose proportionality was observed as steady-state bosentan plasma concentrations and AUCs were similar at oral doses of 2 and 4 mg/kg (AUC: 3,577 ng·h/mL and 3,371 ng·h/mL for 2 mg/kg twice daily and 4 mg/kg twice daily, respectively).
Nije primijećena proporcionalnost s dozom budući da su koncentracija bosentana u plazmi i AUC u stanju dinamičke ravnoteže bili slični kod doza od 2 i 4 mg/kg primijenjenih peroralno (AUCτ: 3577 ng•h/mL za 2 mg/kg dvaput dnevno i 3371 ng•h/mL za 4 mg/kg dvaput dnevno).
No dose recommendation can be made.
ili karbamazepina nije ispitana.
No dose recommendations
Nije moguće dati preporuke o
No Dose Reduction
Bez smanjenja doze
No dose reduction is required for concomitant use of amiodarone, quinidine or verapamil (see section 4.5).
Nije potrebno sniženje doze kod istovremene primjene amiodarona, kinidina ili verapamila (vidjeti dio 4.5).
No dose reduction of YERVOY is recommended.
a Ne preporučuje se smanjivati dozu lijeka YERVOY.
No dose reduction.
Ne smanjivati dozu.
No dose reductions are recommended, but delay or discontinuation of temozolomide administration should be decided weekly according to haematological and non-haematological toxicity criteria.
Ne preporučuje se smanjivanje doze lijeka, ali svakog tjedna treba odlučiti o odgodi ili prekidu primjene TMZ-a prema kriterijima hematološke i nehematološke toksičnosti.
No dose reductions of Gazyvaro are recommended.
Ne preporučuje se smanjivati dozu lijeka Gazyvaro.
No dose reductions other than those recommended for all patients are necessary (see sections 4.4 and 5.1).
Nisu potrebna druga smanjenja doze osim onih preporučenih za sve bolesnike (vidjeti dijelove 4.4 i 5.1).
No dose separation or dosage adjustment necessary (see Antacids).
Nije potrebno odvajati doze ili ih prilagođavati (vidjeti dio Antacidi).
No dose- and time-dependence was observed in the clearance of saxagliptin and its major metabolite over 14 days of once-daily dosing with saxagliptin at doses ranging from 2.5 mg to 400 mg.
Klirens saksagliptina i njegova glavnog metabolita nisu bili ovisni o dozi ni o vremenu tijekom 14 dana primjene saksagliptina u rasponu doza od 2,5 mg do 400 mg jedanput na dan.
No dose-adjustment is needed when Betmiga is combined with inhibitors of CYP3A and/or P-gp.
Nije potrebno prilagoĎavanje doze kada se Betmiga kombinira s inhibitorima CYP3A i/ili P-gp.
No dose-adjustment of isoniazid or pyrazinamide is required during co-administration with bedaquiline.
Tijekom istovremene primjene s bedakilinom, nije potrebna prilagodba doze izonijazida ili pirazinamida.
No dose-dependent trends were observed in the ADR profile of Velphoro.
U profilu nuspojava na lijek Velphoro nisu uočeni trendovi ovisni o dozi.
No dose-limiting toxicities were observed during clinical trials in RA or CAPS patients.
Tijekom kliničkih ispitivanja nije primijećena dozno-limitirajuća toksičnost u bolesnika s RA ili CAPS-om.
No dose-limiting toxicities were observed during clinical trials in RA patients.
Tijekom kliničkih ispitivanja nije primijećena dozno-limitirajuća toksičnost u bolesnika s RA.
No dosing adjustment is required in patients with mild hepatic impairment but patients should be closely monitored (see sections 4.2 and 4.4).
Nije potrebno podešavanje doza za bolesnike s blagim oštećenjem jetre, ali se bolesnici moraju pažljivo pratiti (vidjeti dijelove 4.2 i 4.4).
No dosing adjustments are recommended in the presence of moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole, diltiazem, verapamil and grapefruit juice).
Ne preporučuje se prilagodba doze u prisutnosti umjerenih inhibitora CYP3A4 (npr., eritromicina, flukonazola, diltiazema, verapamila i soka od grejpa).
No dosing adjustments are required for adult patients based on gender, weight, ethnicity, HIV positivity, or elderly (see section 5.2).
Nije potrebna prilagodba doze u odraslih bolesnika na temelju spola, tjelesne težine, etniciteta, HIV- pozitivnog statusa, ili u starijih osoba (vidjeti dio 5.2).
No dosing recommendations
Ne postoje preporuke o doziranju
No dosing recommendations can be made regarding the use of EVOTAZ with oral contraceptives (see section 4.5).
Nije moguće dati preporuke za doziranje kod primjene lijeka EVOTAZ s oralnim kontraceptivima (vidjeti dio 4.5).
No dosing recommendations can be made regarding the use of Tybost with oral contraceptives.
Nije moguće dati preporuke za doziranje u vezi s primjenom lijeka Tybost s oralnim kontraceptivima.
No drug interaction studies have been performed with Feraccru.
Nisu provedena ispitivanja interakcija Feraccrua s drugim lijekovima.
No drug interaction studies have been performed.
Ispitivanja interakcija lijekova nisu izvođena.
No drug interaction studies have been performed.
Ispitivanja interakcija lijekova nisu provedena.
No drug interaction studies.
Fenobarbital
No drug interaction studies.
interakcija lijeka.
No drug interaction studies.
lijekovima FPV/RTV)
No drug interaction studies.
Nije bilo ispitivanja
No drug interaction studies.
Nije bilo ispitivanja interakcija
No drug interaction study has been performed for the co- administration of REYATAZ with benzodiazepines.
Nisu provedena ispitivanja interakcija lijekova kod istovremene primjene lijeka REYATAZ i benzodiazepina.
No drug interactions were observed in field studies where oclacitinib was administered concomitantly with veterinary medicinal products such as endo- and ectoparasiticides, antimicrobials and anti- inflammatories.
U terenskim ispitivanjima nisu uočene interakcije kada je oclacitinib primjenjivan usporedno sa drugim VMP, kao što su endo- ili ektoparazitici, antibiotici i protuupalni veterinarsko-medicinski proizvodi.
No drug interactions were observed in field studies where oclacitinib was administered concomitantly with veterinary medicinal products such as endo- and ectoparasiticides, antimicrobials and anti- inflammatories.
U terenskim ispitivanjima nisu uočene interakcije kada je oclacitinib primjenjivan usporedno sa drugim VMP, kao što su endo- ili ektoparazitici, antibiotici ili protuupalni veterinarsko-medicinski proizvodi.
No drug-drug interaction studies have been performed.
Nisu provedena ispitivanja interakcija lijekova.
No DRV use
Bez primjene DRV
No effect = 1.00
Bez učinka = 1,00
No effect = 1.00.
Bez učinka = 1,00.
no effect is expected.
gubitkom terapijskog učinka
No effect of agomelatine is documented in patients ≥75 years, therefore agomelatine should not be used by patients in this age group (see also sections 4.2 and 5.1).
Nije zabilježen učinak agomelatina u bolesnika ≥ 75 godina, zbog toga se agomelatin ne bi trebao primjenjivati kod bolesnika ove dobne skupine (vidjeti također dijelove 4.2 i 5.1).
No effect of Ceplene and interleukin-2 was seen in patients in second or later remission.
Djelovanje lijekova Ceplene i interleukin-2 nije uočeno u bolesnika u drugoj ili narednim remisijama.
No effect of inhaled nitric oxide has been documented in newborn babies with a malformation where the diaphragm is not fully complete, so called ‘congenital diaphragmatic hernia’.
Nisu zabilježeni nikakvi učinci inhalacije dušikovog (II) oksida u novorođenčadi s malformacijom kod koje dijafragma (ošit) nije potpuno razvijena, takozvanom prirođenom dijafragmalnom kilom.
No effect of prednisone on the pharmacokinetics of docetaxel was observed.
Nije zabilježen utjecaj prednizona na farmakokinetiku docetaksela.
No effect of race was identified in the population analysis.
U populacijskoj analizi nije primijećen utjecaj rase.
No effect on blood pressure was observed when nitroglycerin was taken 24 hours after administration of a single dose of vardenafil 20 mg film-coated tablet.
Nije primijećen učinak na krvni tlak kad se nitroglicerin uzeo 24 sata nakon primjene jednokratne doze vardenafil 20 mg filmom obložene tablete.
No effect on blood pressure was observed when nitroglycerin was taken 24 hours after administration of a single dose of vardenafil 20 mg film-coated tablets.
Nije primijećen učinak na krvni tlak kad se nitroglicerin uzeo 24 sata nakon primjene jednokratne doze vardenafil 20 mg filmom obložene tablete.
No effect on fertility has been observed in animal studies.
U ispitivanjima na životinjama nije opažen učinak na plodnost.
No effect on male or female fertility has been observed in rats following intravenous verteporfin doses of up to 10 mg/kg/day (approximately 60 and 40-fold human exposure at 6 mg/m2 based on AUCinf in male and female rats, respectively).
Nisu zapaženi nikakvi učinci na plodnost mužjaka ili ženki štakora nakon intravenske primjene doza verteporfina od najviše 10 mg/kg/dan (približno 60 puta odnosno 40 puta veće od izloženosti u ljudi od 6 mg/m2 na temelju vrijednosti AUCinf u mužjaka odnosno ženki štakora).
No effect on the bioavailability of MPA was observed.
Nije primijećen utjecaj na biorasploživost MPA.
No effect on the bioavailability of MPA was observed.
Nije primijećen utjecaj na bioraspoloživost MPA.
No effect on the bioavailability of MPA was observed.
Nije primijećen učinak na bioraspoloživost MPA.
No effect on the metabolite profile of piperaquine in human hepatocytes was observed when piperaquine was co-incubated withartenimol.
Nije opažen učinak na profil metabolita piperakina u ljudskim hepatocitima kad se piperakin inkubirao zajedno s artenimolom.
No effect on umeclidinium AUC or Cmax was observed at a dose 4-fold higher than the therapeutic dose.
Pri primjeni doze četverostruko veće od terapijske nije primijećen učinak na AUC niti Cmax umeklidinija.
No effect on unbound
Nema učinka na
No effect was observed on the fertility of male and female rats or gestation in rats.
Nije uočen učinak na plodnost štakora (muških i ženskih), kao ni utjecaj na gestaciju.
No effects are known.
Nema poznatih učinaka.
No effects of Hizentra on the ability to drive and use machines are expected.
Nema očekivanog utjecaja Hizentre na sposobnost upravljanja vozilima i strojevima.
No effects on ability to drive or use machines have been observed.
Nije zabilježen utjecaj lijeka na sposobnost upravljanja vozilima i rada sa strojevima.
No effects on ability to drive or use machines have been observed.
Nisu primijećeni učinci na sposobnost upravljanja motornim vozilima i strojevima.
No effects on F1 fertility parameters were observed in rats and mice.
Kod štakora i miševa nisu uočeni utjecaji na F1 parametre plodnosti.
No effects on fertility or early embryonic development were noted in animals (see section 5.3).
Nisu primijećeni učinci na plodnost ili rani embrionalni razvoj u životinja (vidjeti dio 5.3).
No effects on fertility or embryofoetal development were observed in rats and rabbits, except at doses related to maternal toxicity.
Nisu zabilježeni nikakvi učinci na plodnost ili embriofetalni razvoj u štakora i zečeva, osim pri dozama koje su toksične za majku.
No effects on male fertility were seen in reproductive studies in male rats.
Nisu primijećeni učinci na mušku plodnost tijekom ispitivanja učinaka na reprodukciju na mužjacima štakora.
No effects on male fertility were seen in reproductive studies in male rats.
U istraživanjima reproduktivnosti nisu opaženi učinci na plodnost mužjaka u štakora.
No effects on male or female fertility and reproductive performance indices were observed at ≤100 mg/kg/day (yielding exposures approximately 8 times those obtained with the maximum recommended human dose of the ivacaftor component of Orkambi based on summed AUCs of ivacaftor and its metabolites extrapolated from Day 90 exposures at 100 mg/kg/day in the 6-month repeat-dose toxicity study in this species).
Nisu opaženi učinci na indekse plodnosti i reproduktivne sposobnosti u mužjaka i ženki pri dozi ≤ 100 mg/kg na dan (pri čemu su izloženosti približno 8 puta veće od onih kod najveće preporučene doze u ljudi za ivakaftor kao komponentu lijeka Orkambi na temelju zbroja AUC-a ivakaftora i njegovih metabolita, ekstrapoliranih iz izloženosti 90. dana pri 100 mg/kg na dan u 6-mjesečnom ispitivanju toksičnosti ponovljene doze provedenom za tu životinjsku vrstu).
No effects on male or female fertility are anticipated from the use of AZARGA.
Učinak AZARGE na plodnost kod muškaraca ili žena nije očekivan.
No effects on male or female fertility have been observed in reproductive toxicity studies in rats (see section 5.3).
U ispitivanjima reproduktivne toksičnosti u štakora, nije primijećen učinak na plodnost mužjaka ili ženki (vidjeti dio 5.3).
No effects on QT interval (corrected using either the Fridericia or Bazett method or individually- corrected) were observed when aclidinium bromide (200 µg or 800 µg) was administered once daily for 3 days to healthy subjects in a thorough QT study.
Nisu zabilježeni učinci na QT interval (korigiran bilo metodom Fridericia ili Bazett ili individualno) kod primjene aklidinijeva bromida (200 µg ili 800 µg) jednom dnevno tijekom 3 dana zdravim ispitanicima tijekom cijelog QT ispitivanja.
No effects on sperm count/motility or on fertility were noted in male and female rats up to the highest tested dose, approximately 5 times the recommended dosage for humans.
Nije zamijećeno djelovanje na broj/pokretljivost sperme ili na fertilitet u muških i ženskih štakora čak s najvišim ispitivanim dozama, koje su približno 5 puta veće od preporučene doze za primjenu u ljudi.
No effects on the ability to drive or use machines are expected.
Ne očekuje se utjecaj na sposobnost upravljanja vozilima i strojevima.
No effects were observed on males and females fertility in animal studies.
Nisu uočeni učinci na plodnost mužjaka i ženki u istraživanjima na životinjama.
No effects were seen on the pharmacokinetics of the COMT substrate carbidopa.
Nisu opaženi učinci na farmakokinetiku COMT- ovog supstrata karbidope.
No efficacy data are available concerning the use of the vaccine in male animals.
Ne postoje podaci o učinkovitosti vakcine COXEVAC pri korištenju u muških životinja.
No efficacy has been demonstrated in these animals.
Kod ovih životinja se nije pokazala učinkovitost cjepiva.
No embryonal/foetal toxicities were seen in studies in pregnant rats and rabbits with the exception of decreased foetal body weights in rats at doses associated with maternal toxicities (see section 5.3).
Nije dokazana embrionalna ili fetalna toksičnost u studijama na skotnim štakorima i kunićima, osim smanjenja težine fetusa u štakora u dozama povezanim s toksičnošću za majku (vidjeti dio 5.3).
No embryonal/foetal toxicities were seen in studies in pregnant rats and rabbits with the exception of decreased foetalbody weights in rats at doses associated with maternal toxicities (see section 5.3).
Nije dokazana embrionalna ili fetalna toksičnost u studijama na oplođenim štakorima i zečevima, osim smanjenja težine fetusa u štakora u dozama toksičnim za oplođenu ženku (vidjeti dio 5.3).
No embryotoxicity or malformations were observed following intramuscular administration of paliperidone palmitate to pregnant rats up to the highest dose (160 mg/kg/day) corresponding to 4.1 times the exposure level in humans at the maximum recommended dose of 150 mg.
Nakon intramuskularne primjene paliperidonpalmitata skotnim ženkama štakora, pri čemu je s najvišom dozom (160 mg/kg/dan) postignuta 4,1 puta veća razina izloženosti nego uz primjenu najveće preporučene doze za ljude od 150 mg, nisu opažene embriotoksičnost ni malformacije.
No emergent resistance to Stribild was identified in clinical studies of virologically-suppressed patients who switched from a regimen containing a ritonavir-boosted protease inhibitor (PI+RTV) (Study GS-US-236-0115), an NNRTI (Study GS-US-236-0121) or raltegravir (RAL) (Study
U kliničkim ispitivanjima s pacijentima kod kojih je virus suprimiran, a koji su prešli s režima koji je sadržavao ritonavirom pojačani inhibitor proteaze (PI+RTV) (ispitivanje GS-US-236-0115), NNRTI (ispitivanje GS-US-236-0121) ili raltegravir (RAL) (ispitivanje GS-US-236-0123) nije zabilježena novonastala rezistencija na Stribild.
No emesis
Bez emeze
No emesis (no emetic episodes regardless of use of rescue therapy)
Bez povraćanja (izostanak povraćanja bez obzira na dodatne lijekove)
No emesis (no emetic episodes regardless of use of rescue therapy)
Bez povraćanja (izostanak povraćanja bez obzira na primjenu dodatnih lijekova)
No entry
Bez unosa
NO ENTRY
NEMA PODATA KA
NO ENTRY
Nema podataka
No entry
Nema podataka.
NO ENTRY
NEMA UNOSA.
NO ENTRY
Neprimjenjivo
No epidemiological data on the risk of cervical cancer in users of IOA are available.
Nema epidemioloških podataka o riziku od raka vrata maternice u žena koje uzimaju IOA.
No episodes of major hypoglycaemia were observed in the trial with liraglutide used as monotherapy.
U ispitivanju liraglutida u monoterapiji nisu zapažene epizode teže hipoglikemije.
No episodes of major hypoglycaemia were reported, and no subject discontinued the study treatment due to hypoglycaemia (see sections 4.4 and 4.5).
Nije bilo prijavljenih događaja teške hipoglikemije i nijedan ispitanik nije prekinuo ispitivano liječenje zbog hipoglikemije (vidjeti dijelove 4.4 i 4.5).
No episodes of torsade de pointes were observed.
Nisu zapažene epizode torsade de pointes.
No evidence exists that indicates an interaction between epoetin alfa and G-CSF or GM-CSF with regard to haematological differentiation or proliferation of tumour biopsy specimens in vitro.
Nema dokaza koji bi upućivali na interakciju između epoetina alfa i faktora koji stimulira koloniju granulocita (G-CSF, eng.
No evidence exists that indicates an interaction between epoetin alfa and granulocyte colony- stimulating factor (G-CSF) or granulocyte macrophage colony-stimulating factor (GM-CSF) with regard to haematological differentiation or proliferation of tumour biopsy specimens in vitro.
Ne postoje dokazi koji ukazuju na interakciju između epoetina alfa i čimbenika stimulacije granulocitnih kolonija (G-CSF) ili čimbenika stimulacije granulocitnih i makrofagnih kolonija (GM-CSF) s obzirom na hematološku diferencijaciju ili proliferaciju uzoraka biopsije tumora in vitro.
No evidence for mutagenic or genotoxic effects of ambrisentan were seen in bacteria or in two in vivo rodent studies.
Nisu nađeni dokazi mutagenog ili genotoksičnog potencijala ambrisentana na bakterije ili u dvjema in vivo ispitivanjima na glodavcima.
No evidence of a carcinogenic effect was apparent, at inhalation exposures up to the recommended dose (20 ppm), in rats for 20 h/day for up to two years.
Nije bilo dokaza o karcinogenom učinku u štakora u slučaju izloženosti udisanjem do preporučene doze (20 ppm) 20 h/dan u razdoblju do dvije godine.
No evidence of altered toxicity profile was identified in the patient who developed antibodies to siltuximab.
Nije dokazan promijenjen profil toksičnosti u bolesnika koji je razvio protutijela na siltuksimab.
No evidence of an altered safety profile was found in patients who tested positive for antibodies to Vectibix.
Nije utvrđena promjena sigurnosnog profila kod bolesnika koji su bili pozitivni na protutijela na Vectibix.
No evidence of carcinogenicity was observed in a 2-year bioassay in rats at oral doses of fingolimod up to the maximally tolerated dose of 2.5 mg/kg, representing an approximate 50-fold margin based on human systemic exposure (AUC) at the 0.5 mg dose.
Nisu bili zamijećeni dokazi karcinogenosti u dvogodišnjem biološkom testiranju u štakora, uz peroralne doze fingolimoda do maksimalne tolerirane doze od 2,5 mg/kg, što predstavlja približno 50- erostruko veću vrijednost u odnosu na sistemsku izloženost (AUC) kod ljudi pri dozi od 0,5 mg.
No evidence of direct foetal toxicity or teratogenic effects were observed for ibandronic acid in intravenously treated rats and rabbits.
Nije bilo dokaza izravne fetalne toksičnosti ili teratogenog učinka u štakora i kunića kojima je ibandronatna kiselina primijenjena intravenski.
No evidence of genotoxicity was observed in an Ames microbial mutagenicity assay, a mammalian- cell gene mutation assay, and a transformation assay with Syrian hamster embryo cells.
Nije bilo dokaza genotoksičnosti u Amesovom testu mikrobne mutagenosti, testu genske mutacije na stanicama sisavaca te transformacijskom testu na stanicama embrija sirijskog hrčka.
No evidence of leukaemia (NEL)
Nema dokaza leukemije (NDL)
No evidence of MAO-A inhibition was observed in Phase 1 studies specifically designed to investigate the potential for this interaction.
Nije zabilježen dokaz o inhibiciji MAO-A u ispitivanjima faze 1 koja su posebno dizajnirana kako bi se proučio potencijal za tu interakciju.